Fox Gregory J, Nhung Nguyen Viet, Sy Dinh Ngoc, Britton Warwick J, Marks Guy B
Woolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, NSW 2037, Australia.
Trials. 2013 Oct 20;14:342. doi: 10.1186/1745-6215-14-342.
Tuberculosis is an infectious disease that continues to cause considerable morbidity and mortality globally. Only 65% of patients worldwide are currently diagnosed. Contact investigation is a strategy that aims to increase case detection and reduce transmission of tuberculosis, yet there is little evidence to show its effectiveness.
METHODS/DESIGN: We will conduct a cluster randomized controlled trial of contact investigation within the national tuberculosis control program of Vietnam. Household contacts of patients with smear-positive pulmonary tuberculosis will be invited to attend district tuberculosis units for symptom screening, examination, and chest radiography on four occasions over a two-year period. The primary endpoint is clinically confirmed tuberculosis among contacts during the 24 months of follow-up, ascertained using capture-recapture analysis. Microbiologically proven tuberculosis and treatment completion rates among contacts diagnosed with tuberculosis will be secondary endpoints. The incremental cost-effectiveness ratio will be estimated. The study will have 80% power to detect a 50% increase in the primary endpoint in the active intervention arm compared with the control arm. The study will include 8,829 contacts in each of the active screening and control groups, within 70 districts in 8 provinces in Vietnam, in both rural and urban settings.
The effectiveness of contact investigation as a tool for improved tuberculosis case finding has not been established. This cluster randomized trial will provide valuable operational information for national tuberculosis programs in high-prevalence countries, in order to select the most cost-effective strategies to improve tuberculosis case detection.
The ACT2 study has been registered with the Australian New Zealand Clinical Trials Registry (ACTRN12610000600044).
结核病是一种传染病,在全球范围内仍导致相当高的发病率和死亡率。目前全球仅有65%的患者得到诊断。接触者调查是一种旨在增加病例发现并减少结核病传播的策略,但几乎没有证据表明其有效性。
方法/设计:我们将在越南国家结核病控制项目内开展一项关于接触者调查的整群随机对照试验。涂片阳性肺结核患者的家庭接触者将被邀请到地区结核病防治单位,在两年时间内分四次进行症状筛查、检查和胸部X光摄影。主要终点是随访24个月期间接触者中临床确诊的结核病,通过捕获再捕获分析确定。接触者中微生物学确诊的结核病及治疗完成率将作为次要终点。将估算增量成本效益比。该研究将有80%的把握度检测出与对照组相比,积极干预组主要终点增加50%。该研究将在越南8个省的70个地区的农村和城市地区,在积极筛查组和对照组各纳入8829名接触者。
接触者调查作为一种改善结核病病例发现的工具,其有效性尚未得到证实。这项整群随机试验将为高流行国家的国家结核病项目提供有价值的操作信息,以便选择最具成本效益的策略来改善结核病病例发现。
ACT2研究已在澳大利亚新西兰临床试验注册中心注册(ACTRN12610000600044)。